Market Overview

Vetr Calls For A Hold On Johnson & Johnson Amid Sector Competition

Related JNJ
Pharma ETFs Down Post Q3 Earnings
A Dividend ETF For November And Beyond
Stocks to watch next week (Seeking Alpha)

On Monday, the Vetr crowd downgraded their rating for Johnson & Johnson (NYSE: JNJ) from 3.5 stars (Buy), issued three days ago, to 3 stars (Hold). Crowd sentiment for the stock is mostly positive, with 66 percent of Vetr user ratings bullish.

After hitting an all-time high above $125 earlier in the year, Johnson & Johnson is still performing well despite increased competition from other pharmaceutical companies. The stock traded recently at around $15 per share.

In the wake of the recent market action from other biopharmas, Barclays downgraded Johnson & Johnson from Overweight to Equal-weight late in November.

See how crowdsourced ratings could help you time the market.

Currently, the Vetr crowd's average target price for the stock is at $115.95, which is below the average analyst target price of $120.60. Less than 2 percent of Vetr users are holding JNJ in their watch lists.

Latest Ratings for JNJ

Oct 2017CitigroupMaintainsBuy
Oct 2017Credit SuisseMaintainsOutperform
Oct 2017BarclaysMaintainsEqual-Weight

View More Analyst Ratings for JNJ
View the Latest Analyst Ratings

Posted-In: VetrBiotech Upgrades Crowdsourcing Analyst Ratings General


Related Articles (JNJ)

View Comments and Join the Discussion!

Partner Center